

**ADACEL (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)**

Adacel is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

**IMPORTANT SAFETY INFORMATION FOR ADACEL (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)**

Adacel is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause.

If Guillain-Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid-containing vaccine or if progressive or unstable neurologic disorders exist, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid-containing vaccine.

Syncope can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

**Please see the full [Prescribing Information](#) for Adacel**